Cancer Diagnosis in Patients with Heart Failure: Epidemiology, Clinical Implications and Gaps in Knowledge
Pietro Ameri(Ospedale Policlinico San Martino), Carlo G. Tocchetti(Federico II University Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Gerasimos Filippatos(National and Kapodistrian University of Athens), Rudolf A. de Boer(University Medical Center Groningen), Frank Ruschitska(University Hospital of Zurich), Stephan von Haehling(University of Göttingen), Andrew J.S. Coats(IRCCS Ospedale San Raffaele), Fortunato Ciardiello(University of Naples Federico II), Mitja Lainščak, Dimitrios Farmakis, Alexander R. Lyon(Royal Brompton Hospital), Radek Pudil(Charles University), Marco Canepa(Ospedale Policlinico San Martino), Jutta Bergler‐Klein, Petar Seferović, Alain Cohen‐Solal(Hôpital Lariboisière), Markus S. Anker(Berlin-Brandenburger Centrum für Regenerative Therapien), Thomas Suter, Yu. N. Belenkov
Cited by 183
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k